Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (GB:0VAU)
LSE:0VAU
RESEARCH TOOLSreports
Oncolytics Biotech (0VAU) Share Price & Analysis
1 Followers
0VAU Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Oncolytics Biotech News
PremiumCompany Announcements
Oncolytics Biotech Showcases Cancer Advances at ASCO
PremiumCompany Announcements
Oncolytics Biotech to Present at ASCO MeetingPremiumCompany Announcements
Oncolytics Biotech Sets Virtual Annual MeetingPremiumCompany Announcements
Oncolytics Biotech Eyes Milestone in Breast Cancer Trial
PremiumCompany Announcements
Oncolytics Biotech Targets FDA Approval for Cancer Drug
PremiumCompany Announcements
Oncolytics Biotech Showcases at Oncology EventBulls Say, Bears Say
Bulls Say
Clinical DevelopmentPivotal study in HR+/HER2- breast cancer is supported by positive data from its P2 BRACELET-1 study.
Regulatory MilestoneOncolytics is preparing for registration enabling trials by aligning production with European long-term guidelines.
Strategic CollaborationManagement expressed optimism regarding a potential clinical path forward that includes a collaboration with a major biopharmaceutical company.
Bears Say
Capital Raising ConcernsModel gross equity raises could significantly dilute the value of existing shares.
Financial PerformanceOncolytics reported a net loss with a limited cash runway, potentially impacting its financial stability.
Risks To SuccessOncolytics faces multiple risks including clinical development hurdles and competitive pressures.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.61%
Insiders
0.06% Mutual Funds
0.41% Other Institutional Investors
96.92% Public Companies and
Individual Investors
0VAU FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Currently, no data Available
What is Oncolytics Biotech’s market cap?
Currently, no data Available
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is May 03, 2024 which is in 6 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Mar 07, 2024. The company reported -C$0.05 earnings per share for the quarter, beating the consensus estimate of -C$0.148 by C$0.098.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -C$0.11.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 75,419,770 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -C$0.05 in its last earnings report, beating expectations of -C$0.148. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in GB:0VAU
---
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$6.32 (― Upside)
C$6.32 (― Upside)
Blogger Sentiment
Bullish
GB:0VAU Sentiment 66%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.17%
12-Months-Change
Fundamentals
Return on Equity
-101.82%
Trailing 12-Months
Asset Growth
6.85%
Trailing 12-Months
Company Description
Oncolytics Biotech
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
---
0VAU Earnings Call
Q4 2024
0:00 / 0:00
---
0VAU Stock 12 Months Forecast
Average Price Target
―Best Analysts Covering 0VAU
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+13.31%
reiterated a buy rating 11 months ago
Copying Douglas Loe's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +13.31% per trade.
---